Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member., inc. (CRM)’s Stock Rising on Revenue Burst, Analysts Remain Mixed, inc. (NYSE:CRM) announced their second-quarter results last night, and they exceeded expectations, with revenue rising by 38% from a year ago to $1.32 billion. The company was discussed on CNBC’s Fast Money today, where analysts were mixed over the company’s valuation., inc. (NYSE:CRM)

“[…] Benioff [, inc. (NYSE:CRM)’s CEO Marc Benioff], who’s always kind of sandbagging on guidance, was pretty effusive. I mean that was the most bullish I’ve heard him lately. And the stock hadn’t been performing all that great, but then a 38% jump in revenue I thought was huge, so the fact that he raised full-year guidance even though he kind of sandbagged the next quarter, to me that tells me this stock has a lot more ramp to the upside. It got to $61.00 from $56.00 yesterday; I think it’s got more room to the upside,” said FMHR trader Jon Najarian.

On the other hand, the majority of the other analysts weren’t nearly as sold on, inc. (NYSE:CRM)’s potential for future profit growth. A refrain of multiple analysts was the fact that, inc. (NYSE:CRM) has an almost unanimous ‘Buy’ rating on the street, with 23 ‘Buys’, 2 ‘Holds’, and not a single sell rating, which could limit incremental buyers.

While, inc. (NYSE:CRM)’s stock is up 8% today to just over $60, it was up only marginally the rest of the year prior to today, despite consistently strong results. One reason for that is that robust growth for years to come is already built into the stock’s valuation, which is why some analysts feel the stock has already reached its peak for the foreseeable future and that the strong upward push today may be a knee-jerk reaction to the earnings report that will eventually be given back.

“The time to buy this stock was in May or June. This is a really volatile stock, you really want to buy it on those rare occasions that they disappoint investors. You probably don’t want to jump in on a day like today, where it’s the World’s Fair, but you can trade this stock in both directions,” said Josh Brown.

Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!